Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,126.3
24.4 (0.79%)

 

  • STI Straits Times Index
    3,126.3
    24.4 (0.79%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,491.3
    -10.4 (-0.69%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    23,466.4
    -300.3 (-1.26%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,620.9
    13.5 (0.37%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 483.7M
  • Value: 415.3M
  • Rise: 118
  • Fall: 132
  • Unch: 511

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Addvalue Tech0.016+0.003
HGH0.016-0.003
Hatten Land0.048-0.004
CapLand IntCom T2.050-0.010
ThaiBev0.675+0.010
Sembcorp Marine0.083-
Genting Sing0.775+0.015
Blumont0.004-
Singtel2.400+0.020
Mapletree Log Tr1.870-

World Indices

World Indices
Name Last Change
Nasdaq 15,537.7 -245.1
HSI 23,466.4 -300.3
HSCEI 8,323.0 -132.5
Jakarta 6,576.6 +38.1
Nikkei 225 27,935.6
SSE Comp 3,620.9 +13.5
Shanghai A 3,795.3 +14.3
Shanghai B 283.9 -2.1
KOSPI 2,966.6 -1.7

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Tianjin ZX USD TIANJIN ZHONG XIN PHARM GROUP
Quotes 10 Minutes Delayed. Updated at 06 Dec 2021 11:56
Last (USD): 1.060 Change: -0.010 High: 1.060 Remarks: -
Change (%): -0.93 Low: 1.050

Company Background

In the 1950s, with the China government's policy of merging state-owned pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese Medicinal Materials Corpn (TMCM) merged and reorganised the various factories and stores in Tianjin. In December 1992, TMCM was converted from a state-owned enterprise to a company limited by shares whereby shares were issued to legal persons and its employees. In connection therewith, it was renamed Tianjin Traditional Chinese Medicine Group Co Ltd (TTCM). Following the corporatisation of the Company, the shares issued to the employees were traded at the Tianjin Securities Trading Centre.In conjunction with the proposed public offering, TTCM adopted its present name. Pursuant to the restructuring, it became the holding company for the Group.The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).The holding company and ultimate holding company is Tianjin Pharmaceutical Hldgs, a company incorporated in Tianjin, China.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a 0.07522 Trailing EPS (USD) b 0.10048 NAV (USD) c 0.7280
PE a 14.092 Trailing PE d 10.550 Price / NAV c 1.4560
Dividend Yield (%) e 2.489 Cash In Hand (USD) f 0.2494 Issued & Paid-up Shares g 773,443,000
Piotroski F Score 5 Market Cap (M) 1,427.699 Free Float (%) 25.2
Return on Equity (ROE) (%) h 13.802 Revenue Growth (%) TTM i 17.397
Net Earnings Growth (%) j 45.530 Net Debt/Equity k Net Cash
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Construction - Pharmaceuticals: Other
Category Classification China / Medical & Biotechnology
Index Components FTSE ST All-Share Health Care Index / FTSE ST All-Share Index / FTSE ST China Index / FTSE ST Small Cap Index
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 02 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.030
+2.91 %
10 Days -+0.030
+2.91 %
20 Days -+0.010
+0.95 %
Medium Term Return 3 Months --0.220
-17.19 %
6 Months 0.047+0.060
+10.70 %
1 Year 0.047+0.180
+25.80 %
Long Term Return 2 Years 0.089+0.225
+37.60 %
3 Years 0.121+0.170
+32.70 %
5 Years 0.174+0.220
+46.90 %
Annualised Return Annualised --
+8.00 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Tianjin ZX USD SGX 1,427.699 14.092 10.550 1.4560 2.489
Industry China SGX 770.378 23.843 21.001 0.7274 3.459
Medical & Biotechnology SGX 1,027.291 18.959 16.114 1.4732 1.913
Pharmaceuticals: Other SGX 1,972.671 14.226 10.649 1.4698 2.466
Index FSTAS4000 SGX 1,507.251 13.782 7.462 1.9806 3.313
FTSE ST All-Share Health Care Index SGX 2,029.510 18.391 11.603 1.5502 2.592
FTSE ST All-Share Index SGX 5,886.616 43.098 24.052 1.1385 3.170
FTSE ST China Index SGX 3,158.864 12.416 10.480 0.8596 3.537
FTSE ST Small Cap Index SGX 894.103 37.372 14.696 0.9872 3.920
Global Peer HORIZON THERAPEUTICS PLC NASDAQ 22,645.809 58.097 41.035 5.0887 -
Global Peer ICON PLC NASDAQ 22,206.134 66.819 124.788 2.7867 -
Global Peer CATALENT INC NYSE 20,965.394 39.632 38.490 5.2140 -
Global Peer ARGENX SE SPON ADR EACH REP 1 ORD SHS NASDAQ 14,450.458 - - 4.8953 -
Global Peer SHANGHAI FOSUN PHARMACEUTICAL GROUP HKEx 90,982.985 22.105 17.470 2.0025 1.465
Global Peer BAUSCH HEALTH COMPANIES INC NYSE 8,526.925 - - -41.8002 -
Global Peer UNITED THERAPEUTICS CORP NASDAQ 8,376.339 16.271 18.115 2.1872 -
Global Peer JAZZ PHARMACEUTICALS PLC NASDAQ 7,392.334 30.980 - 1.8770 -
Global Peer Kalbe Farma Tbk. IDX 74,996,680.000 27.439 25.052 4.0387 2.125
Global Peer PERRIGO COMPANY PLC NYSE 4,787.771 - - 0.9239 2.502
Other Global Peers LIVZON PHARMACEUTICAL GROUP INC (HKEx), PRESTIGE CONSUMER HEALTHCARE INC (NYSE), CORCEPT THERAPEUTICS INC (NASDAQ), PACIRA BIOSCIENCES INC (NASDAQ), SAGE THERAPEUTICS INC (NASDAQ), REVOLUTION MEDICINES INC (NASDAQ), LUYE PHARMA GROUP LIMITED (HKEx), CASSAVA SCIENCES INC (NASDAQ), SIHUAN PHARMACEUTICAL HOLD GP LTD (HKEx), IRONWOOD PHARMACEUTICALS INC (NASDAQ), SUPERNUS PHARMACEUTICALS INC (NASDAQ), AMARIN CORP ADR EACH REP 1 ORD GBP0.50 (NASDAQ), MEGA (SET), MADRIGAL PHARMACEUTICALS INC (NASDAQ), BLACKMORES LTD (ASX), AXSOME THERAPEUTICS INC (NASDAQ), ENDO INTERNATIONAL PLC (NASDAQ), INNOVIVA INC (NASDAQ), REVANCE THERAPEUTICS INC (NASDAQ), TONG REN TANG TECHNOLOGIES CO (HKEx), CLINUVEL PHARMACEUTICALS LTD (ASX), AMPHASTAR PHARMACEUTICALS INC (NASDAQ), SHANGHAI FUDAN-ZHANGJIAN BIO-PHARM (HKEx), INTERSECT ENT INC (NASDAQ), BELLRING BRANDS INC (NYSE), HBM HLDGS LTD (HKEx), ACLARIS THERAPEUTICS INC (NASDAQ), CATALYST PHARMACEUTICALS INC (NASDAQ), ZOGENIX INC (NASDAQ), ANI PHARMACEUTICALS INC (NASDAQ), YICHANG HEC CHANGJIANG PHARMACTL CO (HKEx), EAGLE PHARMACEUTICALS INC (NASDAQ), OCI INTERNATIONAL HOLDINGS LTD (HKEx), COLLEGIUM PHARMACEUTICAL INC (NASDAQ), ORAMED PHARMACEUTICALS INC (NASDAQ), THERAVANCE BIOPHARMA INC (NASDAQ), Indofarma Tbk. (IDX), ANIKA THERAPEUTICS INC (NASDAQ), AERIE PHARMACEUTICALS INC (NASDAQ), INTERCEPT PHARMACEUTICALS INC (NASDAQ), ALBIREO PHARMA INC (NASDAQ), CONSUN PHARMACEUTICAL GRP LIMITED (HKEx), SHANDONG XINHUA PHARMACEUTICAL CO (HKEx), MARINUS PHARMACEUTICALS INC (NASDAQ), MEI PHARMA INC (NASDAQ), KEMPHARM INC (NASDAQ), VERONA PHARMA SPON ADR EACH REP 8 ORD SHS (NASDAQ), BIODELIVERY SCIENCES INTERNATIONAL (NASDAQ), PLX PHARMA INC (NASDAQ), IM CANNABIS CORP (NASDAQ), AVALO THERAPEUTICS INC (NASDAQ), TONIX PHARMACEUTICALS HLDG CORP (NASDAQ), CTI BIOPHARMA CORP (NASDAQ), SCYNEXIS INC (NASDAQ), GOLDEN THROAT HLDGS GROUP CO LTD (HKEx), DOD (SET), ZYNERBA PHARMACEUTICALS INC (NASDAQ), CLEVER LEAVES HOLDINGS INC (NASDAQ), FLORA GROWTH CORP (NASDAQ), BIOLINE RX LTD SPON ADS EACH REPR 15 ORD SHS (NASDAQ), ASSEMBLY BIOSCIENCES INC (NASDAQ), ANTISENSE THERAPEUTICS (ASX), GT BIOPHARMA INC (NASDAQ), HEPION PHARMACEUTICALS INC (NASDAQ), LIPOCINE INC (NASDAQ), IDT AUSTRALIA LIMITED (ASX), JILIN PROVINCE HUINAN CHANGLONG BIO (HKEx), NATURAL ALTERNATIVES INTERNATIONAL (NASDAQ), ACELRX PHARMACEUTICALS INC (NASDAQ), TIANDA PHARMACEUTICALS LIMITED (HKEx), AGILE THERAPEUTICS INC (NASDAQ), GROVE INC (NASDAQ), LANSEN PHARMACEUTICAL HOLDINGS LTD (HKEx), CUMBERLAND PHARMACEUTICALS INC (NASDAQ), AMPIO PHARMACEUTICALS INC (NYSE American), BIOPHYTIS SPON ADS EACH REP 10 ORD SHS (NASDAQ), YSPSAH (Bursa), VITA LIFE SCIENCES LIMITED (ASX), GALMED PHARMACEUTICALS LTD (NASDAQ), ALTHEA GROUP HOLDINGS LTD (ASX), CHINA HEALTH GROUP INC (HKEx), ACASTI PHARMA INC (NASDAQ), REGULUS THERAPEUTICS INC (NASDAQ), INDAPTUS THERAPEUTICS INC (NASDAQ), Pyridam Farma Tbk (IDX), QUALIGEN THERAPEUTICS INC (NASDAQ), BOTANIX PHARMACEUTICALS LTD (ASX), SCOPUS BIOPHARMA INC (NASDAQ), ENVERIC BIOSCIENCES INC (NASDAQ), ISORAY INC (NYSE American), EVOKE PHARMA INC (NASDAQ), PHARMAUST LIMITED (ASX), INMED PHARMACEUTICALS INC (NASDAQ), HAPPINESS DEVELOPMENT GROUP LIMITED (NASDAQ), CRONOS AUSTRALIA LIMITED (ASX), KIORA PHARMACEUTICALS INC (NASDAQ), NUTRITIONAL GROWTH SOLUTIONS LTD (ASX), SONOMA PHARMACEUTICALS INC (NASDAQ), HEALTH HOUSE INTERNATIONAL LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

More Information Available

More information is available to our subscribers, including:

  • Consensus Estimates
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.